11 Stocks That Will Bounce Back According to Analysts

Page 7 of 10

4. Biohaven Ltd. (NYSE:BHVN)

Year-to-Date Performance: -39.32%

Average Price Target Upside Potential According to Analysts: 160.83%

Number of Hedge Fund Holders: 41

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company. It focuses on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven Ltd. (NYSE:BHVN) ranks among stocks that will bounce back according to analysts.

Leerink Partners analyst Marc Goodman has kept a positive outlook on Biohaven Ltd. (NYSE:BHVN) by maintaining a “Buy” rating on April 28. The analyst believes that the company is working strategically to expand its market by pursuing approval of troriluzole for the treatment of patients with spinocerebellar ataxia (SCA) in the EU, even though the review process can be challenging and the current financial models do not include sales outside of the US. Goodman acknowledges the company’s strong commitment to expand and is also optimistic about the drug’s chances for approval in the US. The US Food and Drug Administration (FDA) accepted to review the New Drug Application (NDA) for troriluzole, the decision for which is expected in the third quarter of 2025. If approved, Biohaven Ltd. (NYSE:BHVN) will be ready to commercialize troriluzole for SCA in the US in 2025.

Page 7 of 10